Aurora Cannabis Announces Second Quarter 2020 Results

Published: February 14, 2020

Aurora Cannabis Announces Second Quarter 2020 Results

Aurora Cannabis Inc., the Canadian company defining the future of cannabis worldwide, announced its financial and operational results for the second quarter of fiscal 2020 ended December 31, 2019.

“Despite delivering modest growth in our core medical and consumer business in Q2, we took immediate and deliberate actions to align our Company to current market conditions,” said Michael Singer, Executive Chairman and Interim CEO, Aurora Cannabis. “As announced last week, being a profitable cannabis company for our investors is the singular near-term focus for Aurora and we have begun to implement a business transformation plan where we intend to manage the business with a high degree of fiscal discipline.”

Second Quarter 2020 Highlights

(Unless otherwise stated, comparisons are made between Fiscal Q2 2020 and Q1 2020 results and are in Canadian dollars)

  • Cannabis net revenue of $63.2 million, excluding provisions, in Q2 2020 compared to $70.8 million in Q1 2020:
    • Canadian and international medical cannabis net revenue of $27.4 million, with Canadian medical net revenue sequentially flat at $25.6 million, and international medical net revenue down from $5.0 million to $1.8 million due to a temporary sales interruption
    • Consumer cannabis net revenue, excluding provisions, of $33.5 million was an increase of 11% from $30.0 million in the previous quarter. Including the $10.6 million provision for returns and price adjustments for prior quarter sales, reported consumer cannabis net revenues were $22.9 million. Also affecting Q2 consumer cannabis net revenue was slower provincial ordering during the quarter, a shift in the market to value brands (Aurora launched “Daily Special” in early February 2020), and the industry-wide impact from the slow pace of retail store licensing
    • Wholesale bulk cannabis net revenues of $2.4 million, a decline from $10.3 million in the previous quarter, due to overall volume declines and the wholesale of lower potency (priced) product
  • Production volume in fiscal Q2 was 30,691 kilograms, in-line with previous expectations as Aurora realigned its cultivation strategy to produce a greater amount of higher value and higher potency strains
  • Cash cost to produce per gram sold remained relatively consistent at $0.88 per gram versus $0.85 per gram last quarter – Aurora intends to maintain this metric below $1.00 per gram
  • Aurora’s medical patient base remained relatively consistent at 90,307
  • Successfully launched Cannabis 2.0 products with sales to provincial distributors commencing on December 17, 2019

Subsequent Events & Business Transformation Plan

Subsequent to the quarter end, the Company made several decisions designed to strategically transform its operations and provide financial flexibility in response to a changing market and regulatory environment, while supporting its long-term growth:

  • Announced CEO succession plan and expansion of the Board of Directors
  • Executive Chairman Michael Singer appointed Interim CEO, effective February 6, 2020; search for permanent successor underway
  • Two new Independent Directors joined the Board for a total of 10 directors, including 7 Independents
  • Announced comprehensive transformation plan to significantly reduce the Company’s expense base, rationalize capital expenditures, and better align its balance sheet with current market conditions
  • Secured credit facility amendments that remove EBITDA ratio covenants and provided additional financial flexibility as Aurora executes transformation plan

“The transformational actions we announced last week have already positively impacted SG&A expense and we are confident that our run-rate will be approximately $40 million – $45 million as we exit the fiscal fourth quarter of 2020.  This is a very important step toward EBITDA profitability,” said Glen Ibbott, CFO. “In addition, our credit facility was amended to provide greater flexibility to Aurora. More specifically, Aurora chose to downsize the facility by $96.5 million with the elimination of undrawn term loan capacity, and further used $45 million of restricted cash to repay a portion of the drawn term loan balance for the purpose of reducing leverage and cash required for debt service.”

Following these facility changes, Aurora’s current credit facility and other debt outstanding includes:

  • $50 million revolving facility, of which $2 million was drawn as of December 31, 2019
  • $162 million of fully drawn senior secured term loans
  • US$345 million of senior unsecured convertible debentures due February 2024

Q2 2020 Key Financial and Operational Metrics

($ thousands, except Operational Results)

Q2 2020

Q1 2020 (4)

$ Change


Financial Results

Total net revenue(4)





Cannabis net revenue (1)(2a) (4)





Canadian and international medical cannabis net revenue (1)(2a)





Consumer cannabis net revenue (1)(2a)





Wholesale bulk cannabis net revenue (1)(2a)





Gross margin before FV adjustments on cannabis net revenue (1)(2b)





Gross margin before FV adjustments on medical cannabis net revenue (1)(2b)





Gross margin before FV adjustments on consumer cannabis net revenue (1)(2b)





Gross margin before FV adjustments on wholesale bulk cannabis net revenue (1)(2b)





Adjusted gross margin before FV adjustments on cannabis net revenue (1)(2b)





Selling, general and administration expense





Balance Sheet

Working capital





Cannabis inventory and biological assets (1)(3)





Total assets





Operational Results – Cannabis

Cash cost to produce per gram sold (1)(2c)





Active registered patients





Average net selling price of medical cannabis (1)





Average net selling price of consumer cannabis (1)





Average net selling price of wholesale bulk cannabis (1)





Kilograms produced





Kilograms sold






These terms are defined in the “Cautionary Statement Regarding Certain Non-GAAP Performance Measures” section of the MD&A.


Refer to the following sections in the MD&A for reconciliation of non-GAAP measures to the IFRS equivalent measure:


Refer to the “Revenue” section in the MD&A for a reconciliation of cannabis net revenue to the IFRS equivalent.


Refer to the “Gross Margin” section in the MD&A for reconciliation to the IFRS equivalent.


Refer to the “Cash Cost of Sales of Dried Cannabis and Cash Cost to Produce Dried Cannabis Sold – Aurora Produced Cannabis” section of the MD&A for reconciliation to the IFRS equivalent.


Represents total biological assets and cannabis inventory, exclusive of merchandise, accessories, supplies and consumables.


 Includes impact of actual and expected product returns and price adjustments (three and six months ended December 31, 2019 – $10.6 million; three and six months ended December 31, 2018 – nil)


($ thousands)

Three months ended

December 31, 2019

December 31, 2018

Net revenue



Patient counseling services



Analytical testing services



Other cannabis segment revenues (accessories, hemp, other)



Horizontally integrated business revenue



Cannabis net revenue



The table below outlines the breakdown of cannabis net revenue between our medical, consumer and wholesale bulk markets, as well as our dried cannabis and cannabis extracts for the three months ended December 31, 2019 and September 30, 2019.

($ thousands)

Three months ended

December 31, 2019

September 30, 2019

Medical cannabis net revenue

Canada dried cannabis



Canada cannabis extracts (1)



International dried cannabis



International cannabis extracts (1)



Total medical cannabis net revenue



Consumer cannabis net revenue

Dried cannabis



Cannabis extracts (1)



Revenue provisions (2)


Total consumer cannabis net revenue



Wholesale bulk cannabis net revenue

Dried cannabis



Cannabis extracts (1)



Wholesale bulk cannabis net revenue



Total cannabis net revenue




Cannabis extracts revenue includes cannabis oils, capsules, softgels, sprays and topical revenue.


Revenue provisions consists of actual returns and price adjustments of $6.1 million and a $4.5 million revenue provision for estimated future returns and price adjustments

Consolidated net revenue, excluding provisions, was $66.6 million in Q2 2020 as compared to $75.2 million in the prior quarter. Medical cannabis net revenues decreased to $27.4 million in Q2 2020, down 10% over the prior quarter due to a short-term permit issue in Germany (since resolved). Consumer cannabis revenues were $33.5 million ($22.9 million net of provisions) in Q2 2020. The provisions included in cannabis net revenues are comprised of $6.1 million of actual returns and price adjustments and a $4.5 million provision for future returns and price adjustments.

Average net selling price of cannabis, including provisions, decreased to $5.54 per gram over the prior quarter of $5.68. This decrease is attributable to the previously mentioned provision for returns and price adjustments impacting Q2 2020 which did not affect Q1 2020, lower kilograms sold in Q2 versus Q1, and lower wholesale bulk volume and pricing.

Gross margin before fair value adjustments on cannabis net revenue, excluding provisions was 48% in Q2 2020, compared to 58% in the prior quarter.  Including the impact of the return and price adjustment provisions, gross margin before fair value adjustments on cannabis net revenue was 44%.

During Q2 2020, Aurora produced 30,691 kilograms of cannabis as compared to 41,436 kilograms in the prior quarter. The 26% decrease in production output was primarily due to previously announced changes to cultivation strategies, including a pivot to high-value, high-potency strains which are lower yielding. With continued refinement of our cultivation techniques, we expect to achieve quarterly harvest volumes leading to an average of 150,000 kgs annually or better.

Q2 2020 SG&A increased by 23% to $99.9 million from the prior quarter. The increase was primarily driven by a rise in salaries and benefits due to targeted growth in corporate headcount and annual merit increases, investments in educational marketing campaigns related to the launch of Cannabis 2.0 products, and marketing initiatives related to the launch of the Aurora Drift brand.  On February 6, 2020, Aurora announced decisive action effective immediately to reduce SG&A expenses from the Q2 2020 levels, and expects to manage the business with an SG&A expense run-rate of between $40 million to $45 million per quarter exiting Q4 2020 (June 30, 2020).

Adjusted EBITDA(1) loss was $80.2 million in Q2 2020 compared to $39.7 million in Q1 2020. The decline in adjusted EBITDA loss is primarily due to the quarter over quarter decrease in revenue (including provisions), an increase in production costs relating to the ramp up for the legalization of Cannabis 2.0, and the increase in SG&A expenses. Developing a profitable cannabis company in the near term is extremely important to Aurora. While the Company strongly believes the global market opportunity for cannabis is robust, there is uncertainty in the timing of revenue ramp-up in our core markets.  Therefore, the Company has taken action to materially reduce SG&A expenses focused on achieving positive adjusted EBITDA.